PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies

CONCLUSIONS: PAR4 antagonism has additive antithrombotic effects when used in addition to ticagrelor, aspirin, or their combination, in patients with stable coronary heart disease.REGISTRATION: URL:; Unique identifier: NCT05093790.PMID:38357820 | DOI:10.1161/ATVBAHA.123.320448
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Source Type: research